Vistagen Therapeutics, Inc. — FY2013 Form 10-K
Reporting period: Fiscal year ended March 31, 2013; the filing was signed July 18, 2013. The filing is an annual report, not a report for calendar 2012 Q4, although it includes unaudited quarterly results. VistaGen is a development-stage biotechnology company focused on stem-cell-based drug screening and “drug rescue,” with AV-101 as a clinical-stage drug candidate.
Financial performance and position
| Metric | FY2013 | FY2012 |
|---|---|---|
| Revenue | $0.200 million | $1.342 million |
| Research and development expense | $3.431 million | $5.389 million |
| General and administrative expense | $3.563 million | $4.997 million |
| Operating loss | $6.793 million | $9.043 million |
| Net loss | $12.887 million | $12.210 million |
| Net loss attributable to common stockholders | $23.080 million | $12.210 million |
| Cash used in operating activities | $3.463 million | $3.566 million |
- Revenue was primarily grant-related; the NIH AV-101 grant expired June 30, 2012, and the CIRM and subcontract research revenue sources had ended. There were no product sales reported.
- Cash and cash equivalents were $638,100 at March 31, 2013, versus $81,000 a year earlier. Current assets were $671,800 and current liabilities were $2.414 million, leaving a $1.743 million working-capital deficit.
- Total assets were $881,500; total liabilities were $13.438 million; stockholders’ deficit was $12.556 million. The balance sheet included $6.394 million of warrant liability, which is not conventional borrowing.
- Debt included $3.273 million principal of 10% senior secured convertible notes to Platinum, before discounts and accrued interest, and other notes payable. Platinum’s notes are secured by company assets, including intellectual property. The filing lists $2.111 million of future minimum principal payments on long-term debt.
- Gross margin is not meaningful for this development-stage company and is not separately reported.
Changes and unusual items
- Revenue fell about 85% as grant and subcontract funding wound down. Operating expenses declined about 33%, chiefly due to lower R&D and G&A spending, but net loss widened about 6%.
- FY2013 included a $10.193 million noncash deemed dividend related to revised Series A preferred-stock exchange rights. It increased the loss attributable to common stockholders but was not included in reported net loss.
- Other notable FY2013 expenses included a $3.568 million loss on early extinguishment of debt and $1.636 million of noncash expense from changes in warrant and related liability fair values. These accounting items materially affected reported results.
- The company raised financing through $3.3 million of Platinum notes, unit sales, warrant exercises, and debt restructurings. Several service-provider obligations were converted into notes payable only through future share issuance, increasing potential dilution.
Business outlook, risks, and contingencies
- Management expected cash expenditures of approximately $4–6 million over the following 12 months and said it would pursue financing, grants, collaborations, and licensing. It provided no revenue or profitability guidance.
- Management stated that March 31 cash alone was insufficient to fund the next 12 months. The independent auditor’s report raised substantial doubt about the company’s ability to continue as a going concern.
- A post-year-end agreement contemplated $36 million from Autilion for 72 million restricted shares at $0.50 per share. As of the report date, only a nominal initial closing had occurred; the scheduled $475,000 second closing was missed, the agreement was described as in default, and further proceeds were not assured. Completion would cause substantial dilution and could transfer control.
- AV-101 had completed Phase I and Phase 1b development, but further development and commercialization depended on a strategic partner and funding. CardioSafe 3D’s reported validation work was internal and had not undergone peer review or third-party validation; the company had not yet developed a Drug Rescue Variant. LiverSafe 3D remained under development and validation.
- Key risks include financing availability, continued losses and negative operating cash flow, dependence on collaborators, scientific and regulatory uncertainty, competition, intellectual-property and licensing risks, and dilution. No material legal proceedings were reported.
Most important facts for investors to verify
- Whether the Autilion financing closed beyond the nominal initial amount, the current status of the default, and resulting dilution, voting control, and cash proceeds.
- Current cash, monthly cash burn, debt maturities and security interests, and the company’s ability to meet obligations without the proposed financing.
- Progress and independent validation of CardioSafe 3D and LiverSafe 3D, access to drug-rescue candidates, and whether any commercial drug-rescue collaboration or licensing deal has been secured.
- AV-101’s clinical results, next development steps, and availability of a development partner or non-dilutive funding.
- The effects of the preferred-stock exchange rights, warrant repricing and other share-linked obligations on fully diluted ownership and control.